You can buy or sell GBT and other stocks, options, ETFs, and crypto commission-free!
Global Blood Therapeutics, Inc. Common Stock, also called Global Blood Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Read More It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Seeking AlphaMay 15
Global Blood Remains On Track For Transformational Year
Shares of GBT remain conservatively valued and investors can anticipate further appreciation as this story plays out. The company's under-the-radar licensing of inclacumab "completes the package", making Global Blood Therapeutics a force to reckon with in sickle cell disease. Capital Structure Price $58.02 Shares 52,232,448 Market Cap $3,030,526,632.96 Cash & Investments $591,815,000.00 Cash per share $11.33 Debt $0.00 Enterprise Value $2,438,711,632.96 Est. Q. Cash Burn $40,000,000.00 Est. Cash Runway (...
Yahoo FinanceMay 10
Global Blood Reports Narrower-Than-Expected Loss in Q1
Global Blood Therapeutics, Inc. GBT incurred a loss of 87 cents in the first quarter of 2019, which was in line with the loss incurred in the year-ago quarter but narrower than the Zacks Consensus Estimate of a loss of 94 cents. Research and development (R&D) expenses in the first quarter were $34.5 million, up 17.8% year over year. The increase in R&D expenses was mainly due to increased employee-related costs, including non-cash stock compensation, and increased consulting spend associated with NDA filin...
Yahoo FinanceMay 8
When Will Global Blood Therapeutics, Inc. (NASDAQ:GBT) Breakeven?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Global Blood Therapeutics, Inc.'s (NASDAQ:GBT): Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The US$3.1b market-cap company announced a latest loss of -US$174.2m on 31 December 2018 for its most recent financial year result. Many investors are wonderin...
Expected Aug 1, After Hours